header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

General Orthopaedics

MEDIUM- TO LONG-TERM SURVIORSHIP ANALYSIS FOLLOWING COPELAND RESURFACING HEMIARTHROPLASTY

The British Indian Orthopaedic Society (BIOS) Annual Scientific Meeting, Mansfield, England, 7–8 July 2022.



Abstract

Abstract

Background

To determine the long-term survival outcomes of Copeland Resurfacing Hemiarthroplasty (CRHA) performed by a single surgeon series.

Methods

A retrospective cohort study which looked at patients who underwent CRHA over 6 years. Re-operations including revisions with component exchange taking place in our hospital and at local centres were reviewed. Oxford Shoulder Score (OSS) was used to assess their functional outcomes pre- and post-CRHA.

Results

80 CRHAs were performed in 72 patients between 2007 and 2013 with a mean follow-up of 6.5 years. The mean follow-up was 79 months (50–122). The primary indication for CRHA was osteoarthritis (76.3%), cuff tear arthropathy (16.3%), rheumatoid arthritis (5%) and post-trauma (1.3%). The mean pre-operative OSS was 16, which doubled following CRHA surgery. Fifteen patients underwent revision surgery due to ongoing glenoid pain with a mean revision time following primary CRHA being 49 months. Projected survival at the endpoints 5,7 and 10 years were 83, 81 and 79% respectively.

Conclusion

This study provides us with a much longer average follow-up period in comparison to many other studies published. Previous studies, support resurfacing as a useful implant in reducing pain and improving function in the short-term; but this series demonstrates over the medium-term a relatively high revision rate of about 20% in comparison with other arthroplasty options, despite the revision rate seeming to plateau from the 5-year mark onwards.